en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
5/2005
vol. 43
 
Share:
Share:
more
 
 
abstract:

ORIGINAL PAPER
A 6-month trial assessing the safety and efficacy of cyclosporine treatment in patients with active rheumatoid arthritis

Jerzy Świerkot
,
Katarzyna Gruszecka-Marczyńska
,
Jacek Szechiński

Ru 2005, 43; 5: 257-264
Online publish date: 2005/10/27
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 

Objective:
The objective of this study was to determine efficacy and safety of the new generic cyclosporin formulation, Equoral capsules administered in monoterapia or in combination with other disease-modifying anti-rheumatic drugs in patients with active rheumatoid arthritis (RA).
Methods: Thirty patients receiving CsA for RA were prospectively studied over a mean treatment period of 6 months. Initially CsA was given orally 2.5 mg/kg/day. In the course of the observation the dose ranged between 2.5 and 4 mg/kg/day. Clinical evaluation for RA disease activity tender and swollen joint, VASP, patient’s and physician’s global assessments, morning stiffness duration, HAQ, ESR, CRP and treatment side effects was performed prior and to each visit. We studied also the pharmacokinetics of Equoral
The occurence of adverse reactions was noted.
Results: 18 patients (60%) completed 6 months study. Treatment terminations were due to adverse events in 6 cases, inefficacy in 4 patients, poor compliance in 2 patients. In 18 patients who completed 6 months of therapy, a significant improvement was noted compared to baseline in 6 out of 9 clinical disease variables and acute phase reactants. In terms of efficacy at 6 months of follow-up 12 of patients had a ACR 20%, 7 a 50% ACR, 3 a 70% ACR response. The DAS28 index dropped significantly from 4.8±0.9 at baseline visit to 3.3±1.5 (p<0.001) and overall, 13 patients were EULAR responder. In the course of the follow-up period there was a significant decrease in the mean daily dosage of NSAIDs and corticosteroid. Altogether a total of 48 adverse events were reported in 24 patients. Adverse events occured frequently (80%), but only 20% of the patients discontinued CsA permamently.
Conclusion: RA patients treated for six months with CsA showed statistically significant clinical improvement and decrease of inflammation parameters.
In the group of patients treated with CsA side effects were observed often, but rarely caused cessation of therapy.
keywords:

cyclosporine, rheumatoid arthritis







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.